Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).

Other Treatment Options

Routine Prevention Can Help Patients Take Control

Routine prevention may help patients prevent and reduce the frequency and severity of hereditary angioedema (HAE) attacks.1,2

When determining whether prevention treatment is appropriate for an HAE patient, frequency of attacks is not the only criterion.2 Disease severity can be different for each patient, so treatment plans should be personalized based on individual needs.1-3 When evaluating your patients, several important factors should be included in consideration of prevention therapy, and include the following:

  • Frequency of attacks1,3
  • Severity of attacks1,3
  • Past laryngeal attacks4
  • Patient experience and preference1

WAO/EAACI guidelines recommend that patients are evaluated for prevention at every visit.3

Guidelines support exploring preventive treatment as part of an HAE treatment plan. They recommend that patients be evaluated for long-term prevention at every visit, or at least once a year. Patients should also be assessed regularly for efficacy and safety of treatment with the dose or treatment being adapted based on clinical response.3

It is recommended that all attacks are considered for on-demand treatment, especially for attacks affecting the upper airway. Patients should have sufficient on-demand medication available for treatment of 2 attacks and should carry on-demand treatment at all times.3

Collaborative treatment decisions between physicians and patients are critical.1

Patient input is important in determining overall disease burden. When talking with your patients and their caregivers, consider discussing:

  • Therapy administration options1
  • Potential risks and physical benefits of prevention1

You may also want to recommend an on-demand treatment option available for HAE attacks. Click here to learn more about one option to treat HAE attacks in adults.

You might also be interested in:

About CINRYZE Efficacy Self-Administration Training

References

  1. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013;1(5):458–467.
  2. Cicardi M, Bork K, Cabellero T, et al, on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67(2):147-157.
  3. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update [published online ahead of print January 10, 2018]. Allergy. doi:10.1111/all.13384.
  4. Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol. 2008;100(1 Suppl 2):S30–S40.

Definition: